Presentations, Executive Appointments, and Quarterly Financial Reports - Research Report on Jazz Pharmaceuticals, Insulet, The Cooper Companies, Anika Therapeutics, and Sangamo Biosciences Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 6, 2013 NEW YORK, November 6, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ), Insulet Corporation (NASDAQ: PODD), The Cooper Companies Inc. (NYSE: COO), Anika Therapeutics Inc. (NASDAQ: ANIK), and Sangamo Biosciences Inc. (NASDAQ: SGMO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Jazz Pharmaceuticals Public Limited Company Research Report On November 1, 2013, Jazz Pharmaceuticals Public Limited Company (Jazz Pharmaceuticals) announced that it will webcast its corporate presentation at the 2013 Credit Suisse Healthcare Conference on Tuesday, November 12, at 11:30 a.m. MST / 6:30 p.m. GMT in Phoenix, AZ. Jazz Pharmaceuticals reported that the live webcast and its replay (available for at least one week following the presentation) may be accessed through the Company's Investor Relations website. The Full Research Report on Jazz Pharmaceuticals Public Limited Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/5fe3_JAZZ] -- Insulet Corporation Research Report On October 25, 2013, Insulet Corporation (Insulet) announced its participation in three upcoming investor conferences. Insulet will present at the Stephens Fall Investor Conference on Wednesday, November 13, 2013 at 1:00 p.m. ET; The Goldman Sachs Emerging Growth Conference on Thursday, November 14, 2013 at 8:00 a.m. ET; and the 2013 Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 14, 2013 at 1:00 p.m. ET. The Company reported that the live audio webcast and its replay may be accessed through its Investor Relations for 10 days after the presentation. The Full Research Report on Insulet Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/75e4_PODD] -- The Cooper Companies Inc. Research Report On October 30, 2013, The Cooper Companies Inc. (The Cooper Companies) announced the appointment of Daniel G. McBride as the Company's Executive Vice President, Chief Operating Officer, and General Counsel, effective November 1, 2013. Commenting on his appointment, Robert S. Weiss, President and CEO of The Cooper Companies said, "I am very pleased to announce Dan's appointment to this new role. He has been instrumental in supporting our growth and development as a member of my executive team, and this new role will strengthen our focus on achieving our long-term operational goals." The Full Research Report on The Cooper Companies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/9cde_COO] -- Anika Therapeutics Inc. Research Report On October 30, 2013, Anika Therapeutics Inc. (Anika Therapeutics) released its Q3 2013 results. Anika Therapeutics registered total revenues of $17.8 million in Q3 2013, up 20.2% YoY. The Company posted net income of $5.0 million in Q3 2013, up 201.3% YoY and diluted EPS of $0.33 in Q3 2013, up 200.0% YoY. Reflecting on the quarter's performance, Charles H. Sherwood, Ph.D., President and CEO of Anika Therapeutics said, "This was another strong quarter for Anika, driven by continued product revenue growth in our Orthobiologics franchise. Net income and earnings per share rose to third-quarter record high levels, reflecting strong demand for our viscosupplementation products as well as our ongoing initiatives to improve performance across the business. These results measure against a weak set of financial comparatives in the third quarter of 2012, which reflected the temporary decline in product shipments that we experienced in that year-earlier period. Given the positive demand outlook for our Orthobiologics products and the improved efficiencies in our business, we believe that Anika is well-positioned for continued growth and profitability improvement in the quarters ahead." The Full Research Report on Anika Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: efficiencies in our business, we believe that Anika is well-positioned for continued growth and profitability improvement in the quarters ahead [http://www.AnalystsCorner.com/r/full_research_report/ae5d_ANIK] -- Sangamo Biosciences Inc. Research Report On October 23, 2013, Sangamo Biosciences Inc. (Sangamo Biosciences) released its Q3 2013 results. Sangamo Biosciences registered total revenues of $5.7 million, up 16.3% YoY in Q3 2013. According to the Company, Q3 2013 revenues were generated from its collaboration agreements with Shire AG and Sigma-Aldrich Corporation, and research grants. The Company posted a net loss of $6.1 million in Q3 2013, compared to a net loss of $5.8 million in Q3 2012. Sangamo Biosciences reported diluted loss per share of $0.11 in Q3 2013, same as compared to diluted loss per share of $0.11 in Q3 2012. The Full Research Report on Sangamo Biosciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/52a6_SGMO] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Presentations, Executive Appointments, and Quarterly Financial Reports - Research Report on Jazz Pharmaceuticals, Insulet, The
Press spacebar to pause and continue. Press esc to stop.